On Monday, Madrigal Pharmaceuticals got a positive adjustment to its Relative Strength (RS) Rating, from 89 to 92.
This unique rating identifies market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 at the beginning of a new price run.
Looking For The Best Stocks To Buy And Watch? Start Here
Madrigal Pharmaceuticals is working on a cup without handle with a 299.98 entry. See if it can clear the breakout price in volume at least 40% above average.
The company reported 0% EPS growth in its most recent report, while sales growth came in at 0%.
Madrigal Pharmaceuticals holds the No. 165 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and Sarepta Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
